Free Trial
NYSE:CANF

Can-Fite BioPharma (CANF) Stock Price, News & Analysis

Can-Fite BioPharma logo
$2.07 -0.01 (-0.48%)
(As of 04:29 PM ET)

About Can-Fite BioPharma Stock (NYSE:CANF)

Key Stats

Today's Range
$2.03
$2.21
50-Day Range
$1.94
$2.92
52-Week Range
$1.83
$4.69
Volume
87,648 shs
Average Volume
67,785 shs
Market Capitalization
$7.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Strong Buy

Company Overview

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Can-Fite BioPharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
36th Percentile Overall Score

CANF MarketRank™: 

Can-Fite BioPharma scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Can-Fite BioPharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Can-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Can-Fite BioPharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.29) to ($1.11) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Can-Fite BioPharma is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Can-Fite BioPharma is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Can-Fite BioPharma has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CANF.
  • Dividend Yield

    Can-Fite BioPharma does not currently pay a dividend.

  • Dividend Growth

    Can-Fite BioPharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CANF.
  • News Sentiment

    Can-Fite BioPharma has a news sentiment score of -0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Can-Fite BioPharma this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for CANF on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Can-Fite BioPharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.80% of the stock of Can-Fite BioPharma is held by insiders.

  • Percentage Held by Institutions

    Only 21.00% of the stock of Can-Fite BioPharma is held by institutions.

  • Read more about Can-Fite BioPharma's insider trading history.
Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CANF Stock News Headlines

Can-Fite BioPharma Advances in Pancreatic Cancer Trial
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Can-Fite BioPharma Secures Australian Patent for Obesity Drug
See More Headlines

CANF Stock Analysis - Frequently Asked Questions

Can-Fite BioPharma's stock was trading at $2.20 at the beginning of 2024. Since then, CANF shares have decreased by 4.5% and is now trading at $2.10.
View the best growth stocks for 2024 here
.

Can-Fite BioPharma Ltd. (NYSE:CANF) announced its quarterly earnings data on Tuesday, November, 30th. The company reported ($1.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by $1.00. The company earned $0.25 million during the quarter.

Shares of Can-Fite BioPharma reverse split on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Meta Platforms (META), Broadcom (AVGO), Novo Nordisk A/S (NVO) and Adobe (ADBE).

Company Calendar

Last Earnings
11/30/2021
Today
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$18.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+733.3%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$740,000.00
Book Value
$1.76 per share

Miscellaneous

Free Float
3,512,000
Market Cap
$7.65 million
Optionable
Not Optionable
Beta
1.39
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NYSE:CANF) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners